secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-06-09T21:26:27+00:00
Accession:  0001213900-26-066896
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics shareholders approve 600K share increase in stock plan, authorize reverse split
--------------------------------------------------------------------------------

- Stockholders re-elected all five directors: Chase, Dey, Dey, Wurth, Zeidman.
- Approved amendment to 2021 Stock Plan, increasing authorized shares from 61 to 600,061.
- Authorized reverse stock split at ratio 1:2 to 1:20; board has no present intention to implement in next 12 months.
- Ratified Wolf & Company, P.C. as independent auditor for FY2026.
- Stock closed at $4.50 on June 9, compliant with Nasdaq listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/0001213900-26-066896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/ea0294209-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-066896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer